KFA115 + pembrolizumab

KFA115 + pembrolizumab is an investigational **combination therapy** for select advanced cancers. **KFA115** is a novel monoclonal antibody developed by Novartis, believed to target and activate specific elements of the immune system to enhance anti-tumor activity. **Pembrolizumab** is a well-established monoclonal antibody that targets the programmed cell death protein 1 (**PD-1**) pathway, acting as an immune checkpoint inhibitor to promote anti-tumor immune responses. This combination is being studied for safety, tolerability, and preliminary efficacy, particularly in patients who have received prior immunotherapy or are ineligible for currently available PD-1/PD-L1-targeted agents. Indications under investigation include non-small cell lung cancer, renal cell carcinoma, melanoma, high-grade serous ovarian cancer, nasopharyngeal carcinoma, triple-negative breast cancer, anal cancer, mesothelioma, esophagogastric cancer, head and neck squamous cell carcinoma, colon cancer with mismatch repair deficiency (MSI-H CRC), and thymic carcinoma[1][2][3][4][5].